Silicon Valley-based Filipinos introduces innovation in ovarian cancer diagnosis

Share us onShare on FacebookShare on Google+Tweet about this on TwitterEmail this to someone
InterVenn BioSciences Photo 1

Left to right: Gege Xu Ph.D. (Senior Scientist), Kaitlynn Custer (Director Of Clinical Operations), Aldo Carrascoso (Chief Executive Officer and Co-Founder), Elisha Goonatilleke Ph.D. (Instrumentation Scientist), Dan Serie MS (Head Of Data And Computational Biology), Alex Parker (Epidemiologist Consultant), Lieza Danan Ph.D. (Chief Scientific Officer and Co-Founder), Ley Hian Low Ph.D. (Head Of Operations, MY), Widya Mulyasasmita Ph.D. (Chief Business Officer), and Padraig Buckley (Senior Scientist)

Filipino innovators are making their mark as a disruptor in ovarian diagnosis and cancer study with a new blood-based ovarian cancer diagnostic product geared towards early diagnosis and detection.

InterVenn BioSciences, with headquarters in Redwood City California, recently introduced the product which is currently undergoing analytical and clinical validation. The diagnostic product is an accurate minimally invasive blood test to detect ovarian cancer in the early stages.

The life science company aims to understand and control complex diseases like cancer for populations globally. The company uses augmented intelligence (AI) to integrate cancer biology, data science, and advanced instrumentation, all in the context of robust epidemiology study design.

Moreover, the company has developed an AI-Driven Mass Spectrometry-based platform for the discovery and validation of biomarkers for cancer including ovarian, breast, and prostate; pioneering the glycoproteomic approach for the early diagnosis and treatment of cancer.

Glycoproteomics, an emerging field combining proteomics and glycomics, can help with better biomarker and target discovery but produces an enormous amount of data that takes too long to fully analyze and is often difficult to reproduce.

By leveraging mass spectrometry, hi-res characterization of post-translational modifications, and artificial intelligence, InterVenn streamlines and expedites this process and ensures that any variability in the workflow–from the sample collection, processing, and all the way to instrument ingestion– is drastically minimized and the results become supremely reproducible.

“We’ve established a talented team of experts in AI, computational biology, mass spectrometry, software engineering, glycoproteomics, and product development who are dedicated to equipping physicians with a reliable, high-performing and cost-effective tool to change the narrative around ovarian cancer,” explained InterVenn BioSciences Chief Executive Officer, Aldo Carrascoso. “Our company promises to contribute passionately in addressing the problem of cancer with an interdisciplinary approach – microbiology, glycoproteomics, augmented intelligence, social sciences, economics and patients care. We believe the best wayto fix the problem is through a holistic approach,” he added.

Carrascoso is one of three Filipino co-founders of InterVenn BioSciences. Working with him are Lieza Danan, Ph.D who has 20 years of mass spectrometry, analytical chemistry, and instrumentation experience answering complex scientific questions no other analytical tools can address, plus over 10 years extensive experience (with Stemcentrx, Genentech, Sutro Biopharma, among many others) as a technical leader in fast-paced Biopharmaceutical, cGMP Analytical CRO, and Instrumentation Facilities.

InterVenn BioSciences Photo 3

Left to right: At The Medical City for Dr. Lebrilla’s talk on “Employing Protein Post-Translational Modification for Biomarker Discovery in Ovarian Cancer”. Axel Kornerup (InterVenn Country Head), Dr. Jayjay Germar M.D. (Ob-Gynecology/Oncologist, The Medical City), Carlito Lebrilla, Ph.D. (InterVenn Scientific Co-Founder), Beatrice Tiangco MPH, M.D. (InterVenn Country Principal Investigator), Ronald Campos M.D. (Ob-Gynecology/Oncologist, The Medical City), Aldo Carrascoso (InterVenn CEO and co-Founder)

Completing the trio is Carlito Lebrilla, Ph.D, fellow at the American Association for the Advancement of Science and Distinguished Professor at University of California Davis. Lebrilla is considered a pioneer in translational glycoproteomics and mass spectrometry and its application to complex disease understanding biological interrogation.

Filipinos are also at the helm of the software development and cloud infrastructure efforts, InterVenn has a dedicated team based in Ortigas Center, Pasig. “The technology is able to automate tedious work, in effect, supercharging the scientists, making their work faster and easier” emphasized Carrascoso.

Once the validation and regulatory processes are completed, the company will begin offering a laboratory diagnostic test. They have recently received institutional investment of $9.4 Million led by seasoned biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV.

Clinical trials are underway in Philippine General Hospital, National Kidney and Transplant Institute, and The Medical City. They urge the public to contribute to developing and validating this vital blood test for early ovarian cancer detection by providing biological samples and medical information – both from ovarian cancer patients and donors who do not have cancer will be useful.

InterVenn BioSciences Photo 2

Left To right: Hui Helen Xu Ph.D. (Chief Product Officer), Ling Shen MPH, Ph.D. (VP Of Clinical Sciences and Biometrics), Lieza Danan Ph.D. (Chief Scientific Officer and Co-Founder), Dan Serie MS (Head Of Data and Computational Biology), Ley Hian Low Ph.D. (Head Of Operations, MY), Widya Mulyasasmita Ph.D. (Chief Business Officer), Gege Xu Ph.D. (Senior Scientist), Prasanna Ramachandran Ph.D (Senior Scientist – Data And Instrumentation), and Aldo Carrascoso (Chief Executive Officer And Co-Founder)

The 2015 Philippine Cancer Facts and Estimates published by the Philippine Cancer Society identified the ovary as among the top ten leading new cancer sites. While the survival rate is more than 90 percent when detected in the early stages (stage 1), most ovarian cancer cases are diagnosed in the late stages (stage 4) where survival rate is less than 20 percent. Currently, there is no minimally invasive test that can accurately detect ovarian cancer at its early stages when it is most curable.

To be part of their global network of clinical collaborators, contact InterVenn BioSciencesat For more information, please visit,

You may also like...